GSK Takes An Option On Concert’s Preclinical Compounds
This article was originally published in The Pink Sheet Daily
Executive Summary
In the latest in a long string of alliances sporting options, the Big Pharma lends its imprimatur to Concert’s platform for creating deuterated versions of existing molecules.
You may also be interested in...
Glaxo And SuperGen Team Up In An Option Deal For Cancer Targets
GlaxoSmithKline will pay $5 million upfront for an option to develop cancer drugs based on epigenetic targets; deal is GSK's sixth option-alliance this year.
Glaxo And SuperGen Team Up In An Option Deal For Cancer Targets
GlaxoSmithKline will pay $5 million upfront for an option to develop cancer drugs based on epigenetic targets; deal is GSK's sixth option-alliance this year.
Start-Up Quarterly Statistics, Q2 2009
Highlights from the Q2 2009 review of start-up dealmaking: Fundraising in the biopharma, medical device, and in vitro diagnostics industries totaled $864 million--a 25% increase from Q1 2009--with most of the money, 54% or $465 million, coming out of the device industry, which saw only $127 million the previous quarter. There was one acquisition--PPD paid $14.5 million in cash for Magen BioSciences. In the most significant alliance, valued at up to $527 million, GSK got rights to three compounds from Concert Pharmaceuticals, including two in the preclinical stage, which was the most popular phase of development on Q2 alliances.